Novel three-drug combo shows promise in advanced HER2-negative breast cancer treatment

A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investigators from the Johns Hopkins Kimmel Cancer Center.

Related Keywords

California , United States , New York , Ireland , Miami , Florida , American , James Leatherman , Avonne Oconnor , Alexei Hernandez , Johns Hopkins , Michelle Rudek , Elizabeth Engle , Christine Rafie , Evanthia Roussos Torres , Joseph Tandurella , Elizabeth Jaffee , Roisin Connolly , Los Angeles , Robert Anders , Chenguang Wang , Vered Stearns , Qingfeng Zhu , Elana Fertig , Roussos Torres , Sarah Shin , Ludmila Danilova , University Of Pittsburgh Cancer Institute , University College Cork , Yale Cancer Center , Kimmel Cancer Center , Ohio State University , Home Group , Cancer Therapy Evaluation Program , Johns Hopkins University School Of Medicine , National Cancer Institute , Johns Hopkins Kimmel Cancer Center , Parker Institute , Genentech , Johns Hopkins University , University Of Miami Miller School Medicine , University Of Pittsburgh Hillman Cancer Center , Johns Hopkins Kimmel Cancer , Nature Cancer , Southern California Keck School , Johns Hopkins University School , Weill Cornell Medicine , Melinda Downs , Avonneo Connor , Miami Miller School , Pittsburgh Cancer Institute , Hillman Cancer Center , Cedars Sinai Cancer , Ohio State , Medical Home Group , Break Through Cancer , Breast Cancer , Dancer , Growth Factor , Ormone , Immune Response , Immunotherapy , Medicine , Eceptor , Research , Humor ,